Transfection of NF-κB decoy oligodeoxynucleotide suppresses pulmonary metastasis by murine osteosarcoma
A Nishimura1, K Akeda, T Matsubara
1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Mie, Japan.
Abstract:
Nuclear factor-kappa B (NF-κB) has a pivotal role in the progression and distant metastasis of cancers, including malignant bone tumors. To inhibit NF-κB activation, a new molecular therapy using synthetic double-stranded oligodeoxynucleotide (ODN) as a 'decoy' cis element against NF-κB has been developed. To determine whether pulmonary metastasis of osteosarcoma is reduced by inhibiting the action of NF-κB, NF-κB decoy ODN was transfected into the nuclei of murine osteosarcoma cells with high pulmonary metastatic potential, the LM8 cell line, using a three-dimensional alginate spheroid culture model. An in vitro study demonstrated the successful transfection of LM8 cells cultured in alginate beads by 'naked' NF-κB decoy ODN and that the activation of NF-κB signaling was significantly suppressed. Tumor growth was not affected by transfection of NF-κB decoy ODN, however, the expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule 1 (ICAM-1) mRNA was markedly decreased. Furthermore, the transfection of 'naked' NF-κB decoy ODN effectively suppressed pulmonary metastasis in an in vivo alginate bead transplantation model. Our results suggest that NF-κB has a central and specific role in the regulation of tumor metastasis and could be a molecular target for development of anti-metastatic treatments for osteosarcoma.
Insights
Nuclear factor-kappa B (NF-κB) decoy oligodeoxynucleotides (ODN) inhibit osteosarcoma metastasis. This molecular therapy suppressed pulmonary metastasis without affecting tumor growth, targeting NF-κB signaling.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Nuclear factor-kappa B (NF-κB) signaling is implicated in cancer progression and metastasis.
- Osteosarcoma, a malignant bone tumor, often metastasizes to the lungs.
- Targeting NF-κB activation presents a potential therapeutic strategy for inhibiting cancer metastasis.
Purpose of the Study:
- To investigate the efficacy of NF-κB decoy oligodeoxynucleotides (ODN) in inhibiting pulmonary metastasis of osteosarcoma.
- To determine the role of NF-κB in the regulation of tumor metastasis in osteosarcoma.
- To evaluate the potential of NF-κB as a molecular target for anti-metastatic treatments.
Main Methods:
- Utilized a three-dimensional alginate spheroid culture model for transfecting murine osteosarcoma LM8 cells with 'naked' NF-κB decoy ODN.
- Performed in vitro studies to confirm successful transfection and assess NF-κB signaling suppression.
- Employed an in vivo alginate bead transplantation model to evaluate the effect on pulmonary metastasis.
Main Results:
- Demonstrated successful in vitro transfection of LM8 cells and significant suppression of NF-κB signaling.
- Observed no impact on tumor growth but a marked decrease in vascular endothelial growth factor (VEGF) and intercellular adhesion molecule 1 (ICAM-1) mRNA expression.
- Showed effective suppression of pulmonary metastasis in the in vivo model using NF-κB decoy ODN.
Conclusions:
- NF-κB plays a central and specific role in regulating tumor metastasis in osteosarcoma.
- NF-κB decoy ODN therapy effectively inhibits pulmonary metastasis of osteosarcoma.
- NF-κB represents a promising molecular target for developing novel anti-metastatic treatments for osteosarcoma.
